1-6 of 6
Saleem Shariff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Elizabeth Brem, Wojciech Jurczak, David Belada, Jaime Perez de Oteyza, Aranzazu Alonso Alonso, Fevzi Altuntas, Michał Kwiatek, Joshua Brody, Ernesto Perez Persona, Mustafa Yenerel, Monica Tani, Jingxian Cai, Priya Deshpande, Saleem Shariff, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Ashish Risal, Ruemu Birhiray
Journal: Blood
Blood (2024) 144 (Supplement 1): 4411.
https://doi.org/10.1182/blood-2024-200080
Published: 2024
Journal Articles

Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab

Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry
Journal: Blood
Blood (2024) 144 (Supplement 1): 1650.
https://doi.org/10.1182/blood-2024-200166
Published: 2024
Journal Articles

Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

Gottfried von Keudell, Eliza A. Hawkes, Cecilia Carpio, Max S. Topp, Biyi Shen, Jingjin Li, Claire Hearnden, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry, Sabarish Ayyappan
Journal: Blood
Blood (2024) 144 (Supplement 1): 3080.
https://doi.org/10.1182/blood-2024-200623
Published: 2024
Journal Articles

Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry
Journal: Blood
Blood (2024) 144 (Supplement 1): 3076.
https://doi.org/10.1182/blood-2024-200259
Published: 2024
Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Jose. C. Villasboas, Tae Min Kim, Michal Taszner, Silvana Novelli, Seok-Goo Cho, Michele Merli, Ana Jimenez Ubieto, Benoit Tessoulin, Michelle Poon, Jan Walewski, Shuhua Yi, Yuqin Song, Geoffrey Chong, Stefano Luminari, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Wei Zhang, Laura Magnano, Elżbieta Iskierka-Jażdżewska, Monica Tani, Jessica Cai, Amulya Uppala, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, David Tucker
Journal: Blood
Blood (2023) 142 (Supplement 1): 3041.
https://doi.org/10.1182/blood-2023-181650
Published: 2023
Journal Articles

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sabarish Ayyappan, Won Seog Kim, Tae Min Kim, Jan Walewski, Seok-Goo Cho, Isidro Jarque, Elzbieta Iskierka-Jazdzewska, Michelle Poon, Sung Yong Oh, Francesca Lorraine Wei Inng Lim, Cecilia Carpio, Tran-Der Tan, Antonio Gutiérrez, Huilai Zhang, Junning Cao, Mingzhi Zhang, Benoit Tessoulin, Jingjin Li, Melanie Ufkin, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, H. Miles Prince
Journal: Blood
Blood (2023) 142 (Supplement 1): 436.
https://doi.org/10.1182/blood-2023-179818
Published: 2023